Blade Therapeutics successfully completed phase 1 studies evaluating the coadministration of cudetaxestat with existing approved therapies for the treatment of idiopathic pulmonary fibrosis (IPF), according to a news release.

Cudetaxestat is an investigative, noncompetitive autotaxin inhibitor that was developed by Blade Therapeutics for the treatment of IPF and other fibrotic illnesses.

The phase 1 study investigated the properties of cudetaxestat when used together with either pirfenidone or nintedanib (both approved drugs for IPF) in 83 healthy adult participants. For the purpose of the development of this drug, Blade Therapeutics clarified that it was not meant to be curative (for now).

Continue Reading

“Existing treatments slow, but do not prevent, progression of fibrosis and the development of respiratory failure,” Toby Maher, MD, PhD, from USC Hastings Center for Pulmonary Research in Los Angeles, California said.

“This phase 1 study of cudetaxestat provides a clear path to proceed into a phase 2 study that addresses this need for novel therapeutics that may be administered together with current anti-fibrotic drugs.”

Read more about IPF treatment 

Cudetaxestat was chosen as a candidate drug for this clinical study because it has demonstrated direct antifibrotic activity and promising preclinical and biochemical properties that are useful for scientists working towards a treatment profile in lung and liver fibrosis.

Phase 1 studies indicate that it has an acceptable safety profile. “These findings provide confidence in the potential to safely co-administer cudetaxestat on top of the currently approved therapies in patients with uncontrolled IPF,” Wedyne Robbins, MD, president and chief executive officer of Blade Therapeutics said.

With the successful completion of phase 1 trials, Blade Therapeutics is eager to gain approval from regulatory authorities to proceed to the next developmental phase for cudetaxestat. Blade Therapeutics hopes to start a phase 2 clinical trial in the second quarter of 2022.


Blade Therapeutics announces successful completion of phase 1 clinical study that evaluated co-administration of cudetaxestat with either of two approved therapies for idiopathic pulmonary fibrosis. News release. Blade Therapeutics; January 12, 2022.